CURE VENTURES MANAGEMENT, LP

Thesis

Cure Ventures Management, LP is a life sciences venture capital firm founded in 2021 and headquartered in Boston, Massachusetts. The firm specializes in de novo company formation, focusing on groundbreaking curative technologies within the biotechnology and life sciences sectors. Cure Ventures aims to bring cures to market by identifying and enabling companies with exceptional growth potential that address unmet medical needs. Their investment thesis is built on three core tenets: a seed funding model to de-risk early-stage science, a strong emphasis on genetic validation to increase the probability of success, and the involvement of embedded Cure operators to drive day-to-day decision-making in collaboration with founders. The firm focuses on early-stage investments, primarily in new therapeutics, and is particularly interested in disruptive technologies addressing high unmet patient needs. They are committed to working closely with founders, acting as a "sweat equity partner" rather than just a financial investor. The firm's geographic scope is primarily the United States. Their investment stages focus on seed funding, with a minimum check size of $100,000 and a maximum of $2 million. Cure Ventures also provides seed funding ranging from $250,000 to $6 million, with plans to co-lead Series A and B rounds. Cure Ventures launched with an inaugural fund, Cure Ventures Fund I, L.P., closing at $350 million in capital commitments in April 2023.

Related lists

• Seed-stage Healthcare investors
• Series A Healthcare investors
• Series B Healthcare investors